Distribution of Study Participants based on Biopsy Findings (n = 220) Biopsy Findings Frequency Percent Benign 144 65.5 CIN 1 52 23.64 CIN 2 8 3.6 CIN 3
16 7.3 Total 220 100.0 Table 3.
This study comprised 43 women in the control group (mean age 33.8 [+ or -] 9.3), 53 in the CIN 1 group (mean age 32.2 [+ or -] 9.1), 60 in the CIN 2 group (mean age 30.9 [+ or -] 7.5), and 78 in the CIN 3
group (mean age 36.0 [+ or -] 8.4), with ages ranging from 18 to 59 years old.
As for group II, the diagnosis of severe grade of dysplasia of squamous epithelium (CIN 3
) was made in 17 (50%) patients , a moderate dysplasia of squamous epithelium (CIN 2) and mild dysplasia of squamous epithelium (CIN l) was found in 10 (29.41%) and 7 (20.59%) cases, respectively.
Biopsy findings were CIN 2 in 2 patients, CIN 3
in 1 patient, VAIN 2 in 3 patients, and VAIN 3 in 1 patient.
Among 2,796 women (mean age, 39.5 years) who underwent random biopsy, the findings were normal, CIN 1, CIN 2, and CIN 3
in 90.0%, 5.7%, 1.3%, and 1.4%, respectively.
"Cotesting" refers to the combination of cytology and HPV testing, which increases the ability to detect CIN 3
and allows for a decrease in the interval of screening because of the low risk associated with a negative screen.
The statistical analysis was done for normal samples, CIN 1 samples, and CIN 2 and CIN 3
that were analyzed as one group (severe neoplasia).
He pointed out that a few studies have assessed that question, and one concluded that interobserver variation is fair to good for the diagnosis of benign conditions, CIN 3
, or invasive cancer, but poor for the diagnosis of CIN 1 or CIN 2.
In contrast, among the placebo subjects, HPV 16-related CIN 1 was found in 12, CIN 2 in 7, and CIN 3
in 6 (one woman had CIN 2 at one visit and CIN 3
a review of the literature from 1950-1992, showed that as much as 60% of CIN 1 lesions regressed, 30% persisted, 10% progressed to CIN 3
, and only 1 % progressed to invasive cancer."
(3) Despite evidence that intraepithelial lesions classified as CIN 3
are more likely to progress to invasive cancer and less likely to regress than intraepithelial lesions classified as CIN 2, (4) a CIN 2/3 threshold for excision is still generally retained because the distinction between CIN 2 and CIN 3
is not always clear.
With that in mind, we do believe that prudent providers will follow women of this young age who do not have CIN 3
(which does require treatment).